Specific Immunotherapy to Birch Allergen Does not Enhance Suppression of Th2 Cells by CD4+CD25+ Regulatory T Cells During Pollen Season

[1] Bousquet J(1998)Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 102 558-62

[2] Lockey R(1996)Discontinuing venom immunotherapy: outcome after five years J Allergy Clin Immunol 97 579-87

[3] Malling HJ(2002)Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy J Allergy Clin Immunol 109 777-83

[4] Golden DB(2004)Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study Allergy 59 74-80

[5] Kwiterovich KA(1997)Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects Eur J Immunol 27 1131-9

[6] Kagey-Sobotka A(1998)Role of interleukin 10 in specific immunotherapy J Clin Invest 102 98-106

[7] Valentine MD(1999)Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome Clin Exp Allergy 29 497-506

[8] Lichtenstein LM(1998)IgE versus IgG4 production can be differentially regulated by IL-10 J Immunol 160 3555-61

[9] Arvidsson MB(2001)Inhibition of IgE-induced activation of human mast cells by IL-10 Clin Exp Allergy 31 694-704

[10] Lowhagen O(1994)Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils J Exp Med 180 711-5

[1] Bousquet J(1998)Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 102 558-62

[2] Lockey R(1996)Discontinuing venom immunotherapy: outcome after five years J Allergy Clin Immunol 97 579-87

[3] Malling HJ(2002)Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy J Allergy Clin Immunol 109 777-83

[4] Golden DB(2004)Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study Allergy 59 74-80

[5] Kwiterovich KA(1997)Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects Eur J Immunol 27 1131-9

[6] Kagey-Sobotka A(1998)Role of interleukin 10 in specific immunotherapy J Clin Invest 102 98-106

[7] Valentine MD(1999)Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome Clin Exp Allergy 29 497-506

[8] Lichtenstein LM(1998)IgE versus IgG4 production can be differentially regulated by IL-10 J Immunol 160 3555-61

[9] Arvidsson MB(2001)Inhibition of IgE-induced activation of human mast cells by IL-10 Clin Exp Allergy 31 694-704

[10] Lowhagen O(1994)Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils J Exp Med 180 711-5